Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009130 | 0.90 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A | |
| SCHEMBL3471632 | 0.87 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KMT2ARAB9AL3MBTL1 | |
| SCHEMBL14593012 | 0.87 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KMT2ARAB9AL3MBTL1 | |
| SCHEMBL27652100 | 0.85 | CA2 (0.57) | ALDH1A1SMN1; SMN2MEN1KMT2ACA1 | |
| Hydrochloric Acid SCHEMBL11499380 | 0.83 | NPSR1 (0.56) | ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A | |
| SCHEMBL3865205 | 0.83 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2NPSR1L3MBTL1CA1 | |
| SCHEMBL11412681 | 0.82 | CA1 (0.53) | ALDH1A1SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL21962449 | 0.82 | CA2 (0.54) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL11598119 | 0.80 | CA1 (0.60) | CA1CA2CA12CA9CA7 | |
| SCHEMBL27631620 | 0.80 | CA2 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984072-B1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | UNIV PISA (IT) | 2024-05-29 | — | — | EP | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | AZIENDA OSPEDALIERA DI REGGIO EMILIA ARCISPEDALE S. MARIA NUOVA IRCCS (IT) | 2016-03-17 | — | — | US | disclosed |
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | AZIENDA OSPEDALIERA DI REGGIO EMILIA ARCISPEDALE S. MARIA NUOVA IRCCS (IT) | 2016-03-17 | — | — | US | disclosed |
| EP-2984072-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | Universita Di Pisa (IT) | 2016-02-17 | — | — | EP | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| EP-0680972-B1 | Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR (FR) | 2000-03-08 | — | — | EP | disclosed |
| US-5567804-A | HUMAN LEUCOCYTE ELASTASE INHIBITOR; ANTIOXIDANT | ADIR ET COMPAGNIE (FR) | 1996-10-22 | — | — | US | disclosed |
| US-5565429-A | HUMAN LEUCOCYTE ELASTASE INHIBITORS; EMPHYSEMA; ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES | ADIR ET COMPAGNIE (FR) | 1996-10-15 | — | — | US | disclosed |
| EP-0680972-A1 | Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075652-A1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | XDH, XPA, NR1H3 | ALDH1A1 4756/4885SMN1; SMN2 3258/4885NPSR1 2272/4885 |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | ALDH1A1 715/4885SMN1; SMN2 1506/4885NPSR1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.